Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial

Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, Chen P, Söderdahl G, Österborg A, Edvard Smith CI, Wullimann D, Vesterbacka J, Lindgren G, Blixt L, Friman G, Wahren-Borgström E, Nordlander A, Gomez AC, Akber M, Valentini D, Norlin AC, Thalme A, Bogdanovic G, Muschiol S, Nilsson P, Hober S, Loré K, Chen MS, Buggert M, Ljunggren HG, Ljungman P, Aleman S, None

- - (-) - [2021-09-12; online 2021-09-12]

Category: Biochemistry

Category: Health

Category: Vaccines

Funder: KAW/SciLifeLab

Funder: VR

Research Area: High-throughput and high-content serology

Research Area: Vaccine

Type: Preprint

DOI 10.1101/2021.09.07.21263206

Crossref 10.1101/2021.09.07.21263206


Publications 7.0.1